NCT06160531View on ClinicalTrials.gov

Influenza Viral Challenge Study of CC-42344 in Healthy Participants

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 25, 2023

Primary Completion Date

May 3, 2024

Study Completion Date

July 18, 2024

Conditions
Influenza A
Interventions
DRUG

CC-42344

Anti-influenza A agent

DRUG

Placebo

Matching placebo

Trial Locations (1)

E1 2AX

Queen Mary BioEnterprises Innovation Centre, London

Sponsors
All Listed Sponsors
collaborator

hVIVO Services Limited

INDUSTRY

lead

Cocrystal Pharma, Inc.

INDUSTRY